Corporate Report: March 22

NeoGenomics selling 3 million shares, sets price to generate $7.8 million
NeoGenomics Inc., a Fort Myers-based cancer-focused genetic testing service, has priced a public offering of 3.15 million shares of common stock at $3 per share. The company plans to sell 2.85 million shares and The Mary S. Dent Gifting Trust will sell another 300,000 NeoGenomics shares.

The net proceeds to NeoGenomics, after deducting the underwriter's discounts and other estimated offering expenses, is expected to be $7.8 million.

The company plans to use the income to pay down debt and for general corporate and operating purposes.